Li YI, Wei L, Meinsohn M-C, et al. A screen of repurposed drugs identifies AMHR2/MISR2 agonists as potential contraceptives. Proc Natl Acad Sci U S A. 2022;119(15):e2122512119. doi:10.1073/pnas.2122512119.
Wilson FH, Johannessen CM, Piccioni F, et al. A functional landscape of resistance to ALK inhibition in lung cancer. Cancer Cell. 2015;27(3):397-408. doi:10.1016/j.ccell.2015.02.005.
Wan Y, Feng G, Calakos N. Sapap3 deletion causes mGluR5-dependent silencing of AMPAR synapses. J Neurosci. 2011;31(46):16685-91. doi:10.1523/JNEUROSCI.2533-11.2011.
Landau DA, Sun C, Rosebrock D, et al. The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy. Nat Commun. 2017;8(1):2185. doi:10.1038/s41467-017-02329-y.
Sieber J, Wieder N, Clark A, et al. GDC-0879, a BRAF Inhibitor, Protects Kidney Podocytes from Death. Cell Chem Biol. 2018;25(2):175-184.e4. doi:10.1016/j.chembiol.2017.11.006.
Wolach O, Sellar RS, Martinod K, et al. Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. Sci Transl Med. 2018;10(436). doi:10.1126/scitranslmed.aan8292.
Sidhom E-H, Kim C, Kost-Alimova M, et al. Targeting a Braf/Mapk pathway rescues podocyte lipid peroxidation in CoQ-deficiency kidney disease. J Clin Invest. 2021;131(5). doi:10.1172/JCI141380.
Setlur SR, Mertz KD, Hoshida Y, et al. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst. 2008;100(11):815-25. doi:10.1093/jnci/djn150.
Yamamoto S, Wu Z, Russnes HG, et al. JARID1B is a luminal lineage-driving oncogene in breast cancer. Cancer Cell. 2014;25(6):762-77. doi:10.1016/j.ccr.2014.04.024.
MacRae CA, Peterson RT. Zebrafish as tools for drug discovery. Nat Rev Drug Discov. 2015;14(10):721-31. doi:10.1038/nrd4627.